Search

CET and skills guides

Study and gain CET points through OT’s online CET exams, and access archived CET, CPD articles and skills guides in our education library

Find out more

Science and vision

News and features about the latest scientific developments and advances in optometry, ophthalmology and eye medicine

Find out more

Professional support

News and features about the latest developments relating to professional support from across optics. This includes updates from optical organisations such as the AOP and the GOC

Find out more

In practice

News and in-depth features about business management and career development in optics

Find out more

Jobs

Explore the latest UK and global jobs in the optical sector for optometrists, dispensing opticians and more

Find out more

Researchers explore possible uveal melanoma treatment

Pre-clinical trials have identified a molecule inhibitor that limited primary disease and metastatic tumour spread in mice

one green eye
Pixabay/Rudy and Peter Skitterians

Scientists have reported on the potential of a molecule inhibitor that displayed positive effects in a mouse model of uveal melanoma.

Writing in Oncogene, researchers highlighted that the inhibitor, KCN1, limited primary disease in the eye and dampened metastatic tumour spread.

Mice that received treatment with the inhibitor survived for longer without obvious side effects.

Researchers noted that KCN1 was most effective in preventing metastases when it was administered early.

The authors wrote: “Our study suggests that KCN1 has desirable properties as a suppressor of metastasis: It is well tolerated, has excellent distribution to the eye and the liver, and is thus ideally suited for treating metastatic uveal melanoma.”

The authors note that the treatment needs further optimisation before clinical use.

At present, the overall mortality rate for uveal melanoma patients is 50% at five years. This rate has remained unchanged for the past 40 years.

“New therapies are urgently needed,” the authors emphasised.

Advertisement